The ALLHAT Lipid Lowering Trial—Less Is Less
dc.contributor.author | Pasternak, Richard C. | |
dc.date.accessioned | 2019-08-14T15:01:53Z | |
dc.date.available | 2019-08-14T15:01:53Z | |
dc.date.issued | 2002 | |
dc.description.abstract | The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Lipid Lowering Trial (ALLHAT-LLT),1 published in this issue of THE JOURNAL, is the second-largest lipid-lowering trial yet reported. This randomized trial, a subset of the larger ALLHAT hypertension study,2 followed up 10 355 patients (49% women) who had hypertension and were 55 years or older for a mean of 4.8 years. Patients were randomly assigned to receive 40 mg of pravastatin (open label) vs "usual care" in 513 clinical centers, the majority of which were community-based. These centers were a subset of the 623 centers that treated patients for the larger (N = 33 357) ALLHAT hypertension study.2 Despite a 28% reduction in low-density lipoprotein cholesterol (LDL-C) from baseline in the pravastatin treatment group, the trial failed to show a benefit in either the primary outcome (all-cause mortality) or the key secondary outcome (combined nonfatal myocardial infarction and . . . | |
dc.description.uri | http://jama.ama-assn.org/content/288/23/3042.full | |
dc.identifier | https://doi.org/10.13016/bgo0-0wrc | |
dc.identifier.citation | Pasternak, Richard C. (2002) The ALLHAT Lipid Lowering Trial—Less Is Less. JAMA, 288 (23). pp. 3042-3044. | |
dc.identifier.other | Eprint ID 1256 | |
dc.identifier.uri | http://hdl.handle.net/1903/23101 | |
dc.subject | Pharmacotherapy | |
dc.subject | Hypertension | |
dc.subject | studies | |
dc.subject | lipid-lowering trial | |
dc.subject | hypertension study | |
dc.subject | pravastatin | |
dc.title | The ALLHAT Lipid Lowering Trial—Less Is Less | |
dc.type | Article |